Atogepant
Brand name: Qulipta
Rank #291 of 500 drugs by total cost
$40.7M
Total Cost
32,955
Total Claims
$40.7M
Total Cost
1,339
Prescribers
$1,234
Cost per Claim
2,157
Beneficiaries
37,142
30-Day Fills
$30K
Avg Cost/Provider
25
Avg Claims/Provider
About Atogepant
Atogepant (sold as Qulipta) was prescribed 32,955 times by 1,339 Medicare Part D providers in 2023, costing the program $40.7M. At $1,234 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 288 | Pitavastatin Calcium (Livalo) | $40.8M | 69,636 |
| 289 | Bromfenac Sodium (Prolensa) | $40.8M | 121,284 |
| 290 | Suvorexant (Belsomra) | $40.7M | 87,327 |
| 291 | Atogepant (Qulipta) | $40.7M | 32,955 |
| 292 | Obeticholic Acid (Ocaliva) | $40.6M | 4,131 |
| 293 | Doxycycline Hyclate (Doxycycline Hyclate) | $40.5M | 2,023,357 |
| 294 | Carbamazepine (Carbamazepine) | $40.4M | 389,090 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology